These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33091218)

  • 21. Low LDL Cholesterol by PCSK9 Variation Reduces Cardiovascular Mortality.
    Benn M; Tybjærg-Hansen A; Nordestgaard BG
    J Am Coll Cardiol; 2019 Jun; 73(24):3102-3114. PubMed ID: 31221259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 Inhibitors.
    Theocharidou E; Papademetriou M; Reklou A; Sachinidis A; Boutari C; Giouleme O
    Curr Pharm Des; 2018; 24(31):3654-3657. PubMed ID: 30317984
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Lebeau PF; Byun JH; Platko K; Al-Hashimi AA; Lhoták Š; MacDonald ME; Mejia-Benitez A; Prat A; Igdoura SA; Trigatti B; Maclean KN; Seidah NG; Austin RC
    JHEP Rep; 2019 Dec; 1(6):418-429. PubMed ID: 32039393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging Insights on the Diverse Roles of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Chronic Liver Diseases: Cholesterol Metabolism and Beyond.
    Grewal T; Buechler C
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STK25 Regulates Cardiovascular Disease Progression in a Mouse Model of Hypercholesterolemia.
    Cansby E; Magnusson E; Nuñez-Durán E; Amrutkar M; Pedrelli M; Parini P; Hoffmann J; Ståhlman M; Howell BW; Marschall HU; Borén J; Mahlapuu M
    Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1723-1737. PubMed ID: 29930001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.
    Girona J; Ibarretxe D; Plana N; Guaita-Esteruelas S; Amigo N; Heras M; Masana L
    Cardiovasc Diabetol; 2016 Aug; 15(1):107. PubMed ID: 27488210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protective lipid-lowering variants in healthy older individuals without coronary heart disease.
    Lacaze P; Riaz M; Sebra R; Hooper AJ; Pang J; Tiller J; Polekhina G; Tonkin A; Reid C; Zoungas S; Murray AM; Nicholls S; Watts G; Schadt E; McNeil JJ
    Open Heart; 2021 Jul; 8(2):. PubMed ID: 34341098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.
    Ooi TC; Krysa JA; Chaker S; Abujrad H; Mayne J; Henry K; Cousins M; Raymond A; Favreau C; Taljaard M; Chrétien M; Mbikay M; Proctor SD; Vine DF
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3452-3460. PubMed ID: 28673045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of PCSK9 variants on risk of coronary disease and ischaemic stroke.
    Hopewell JC; Malik R; Valdés-Márquez E; Worrall BB; Collins R;
    Eur Heart J; 2018 Feb; 39(5):354-359. PubMed ID: 29020353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic and circulating levels of PCSK9 in morbidly obese patients: Relation with severity of liver steatosis.
    Emma MR; Giannitrapani L; Cabibi D; Porcasi R; Pantuso G; Augello G; Giglio RV; Re NL; Capitano AR; Montalto G; Soresi M; Cervello M
    Biochim Biophys Acta Mol Cell Biol Lipids; 2020 Dec; 1865(12):158792. PubMed ID: 32777481
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience.
    Scicali R; Di Pino A; Urbano F; Ferrara V; Marchisello S; Di Mauro S; Scamporrino A; Filippello A; Rabuazzo AM; Purrello F; Piro S
    Nutr Metab Cardiovasc Dis; 2021 Mar; 31(3):869-879. PubMed ID: 33549441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.
    Humphries SE; Neely RD; Whittall RA; Troutt JS; Konrad RJ; Scartezini M; Li KW; Cooper JA; Acharya J; Neil A
    Clin Chem; 2009 Dec; 55(12):2153-61. PubMed ID: 19797716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Meroni M; Longo M; Lombardi R; Paolini E; Macchi C; Corsini A; Sirtori CR; Fracanzani AL; Ruscica M; Dongiovanni P
    Hepatol Commun; 2022 Mar; 6(3):535-549. PubMed ID: 34677008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression.
    Tao R; Xiong X; DePinho RA; Deng CX; Dong XC
    J Biol Chem; 2013 Oct; 288(41):29252-9. PubMed ID: 23974119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic Glucagon Signaling Regulates PCSK9 and Low-Density Lipoprotein Cholesterol.
    Spolitu S; Okamoto H; Dai W; Zadroga JA; Wittchen ES; Gromada J; Ozcan L
    Circ Res; 2019 Jan; 124(1):38-51. PubMed ID: 30582457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease.
    Grimaudo S; Dongiovanni P; Pihlajamäki J; Eslam M; Yki-Järvinen H; Pipitone RM; Baselli G; Cammà C; Di Marco V; Enea M; Longo M; Pennisi G; Prati D; Zito R; Fracanzani AL; Craxì A; George J; Romeo S; Valenti L; Petta S
    Liver Int; 2021 Nov; 41(11):2712-2719. PubMed ID: 34268860
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD.
    Vilar-Gomez E; Gawrieh S; Liang T; McIntyre AD; Hegele RA; Chalasani N
    J Clin Lipidol; 2021; 15(2):275-291. PubMed ID: 33454241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.